Anuh Pharma Q1 FY27: Higher mix, sharper margins, steady start to FY27

Operating revenue was INR 193.81 crore, EBITDA was INR 19.36 crore and PAT was INR 11.42 crore in Q1 FY27.

EBITDA margin increased to 9.99 percent in Q1 FY27 from 7.34 percent in Q1 FY26, and PBT margin rose to 8.74 percent from 5.87 percent.

Key product revenues in Q1 FY27 included Erythromycin INR 49.1 crore, Higher Macrolides INR 39.9 crore, and Sulphadoxine INR 37.0 crore.

Domestic revenue was INR 124 crore and export revenue was INR 70 crore in Q1 FY27.

Export sales mix in Q1 FY27 was Asia 35.7 percent, Europe 29.6 percent, North America 4.2 percent, Africa 27.9 percent and Latin America 2.6 percent.

The Tarapur site has 9 API blocks and 2 intermediate blocks with total capacity of 2,400 MTPA; the company also has a DSIR approved R and D facility at Mahape of 10,000 sq ft.

The company stated it anticipates a steady growth rate of 15 to 20 percent per annum.